Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405247 · ClinicalTrials.gov registry record
TAURAS - T790 AURA ScreenFailure SOC Registry Study
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 400
- Enrollment target
NCT02405247: Clinical Trial study, sponsored by AstraZeneca.
NCT02405247 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02405247 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 400 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate clinical outcomes of 2nd line therapy in NSCLC patients without the T790M mutation, both independently and when compared indirectly with NSCLC patients with the T790M mutation in the T STAR non interventional study (D5160R00001). The patient population in the TAURAS study will consist of patients who fail screening for AURA3 (D5160C00003) due to a T790M mutation not detected using the central cobas® EGFR Mutation Test (Roche Molecular Systems).
Primary Outcome
This will be assessed as the time from start of 2nd line therapy until the date of disease progression or death by any cause.
Interventions
- OTHER Patient Reported Outcome (PRO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-07 |
Why NCT02405247 stopped before completion
NCT02405247 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Patient Reported Outcome (PRO) is the first listed.
NCT02405247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02405247 about?
NCT02405247 is a clinical study titled "TAURAS - T790 AURA ScreenFailure SOC Registry Study". The aim of this study is to evaluate clinical outcomes of 2nd line therapy in NSCLC patients without the T790M mutation, both independently and when compared indirectly with NSCLC patients with the T790M mutation in the T STAR non interventional study (D5160R00001). The patient population in the TA...
What is the current status of trial NCT02405247?
This trial is currently terminated. The enrollment target is 400 participants. The study started on 2015-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02405247?
The interventions under investigation include: Patient Reported Outcome (PRO) (OTHER).
Who is sponsoring clinical trial NCT02405247?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia